Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
UTC Therapeutics Inc.
Beijing Friendship Hospital
NGM Biopharmaceuticals, Inc
Dublin City University
ImmVira Pharma Co. Ltd
University Hospital, Ghent
Centre Hospitalier Universitaire Vaudois
Kaiser Permanente
Zhejiang University
Immix Biopharma, Inc.
Kineta Inc.
Namida Lab
Shanghai Yunying Medical Technology
MiRXES Pte Ltd
Impact Therapeutics, Inc.
China Medical University Hospital
OncXerna Theraputics, Inc.
Wuhan Ammunition Life-tech Co., Ltd
Blue Note Therapeutics
Revolution Medicines, Inc.
Main Line Health
University Health Network, Toronto
Assistance Publique - Hôpitaux de Paris
Weprom
Jerome Canady Research Institute for Advanced Biological & Technological Sciences
Shanghai Cell Therapy Group Co.,Ltd
Samyang Biopharmaceuticals Corporation
Shenzhen BinDeBio Ltd.
University of Magdeburg
Bay Area Gynecology Oncology
Critical Outcome Technologies Inc.
Placon Therapeutics
Xuanwu Hospital, Beijing
Quantgene Inc.
Mie University
Merrimack Pharmaceuticals
SPGO Research Mannheim GmbH
Shenzhen Second People's Hospital
Chinese PLA General Hospital
Rutgers, The State University of New Jersey
University of Aarhus
National Cancer Institute (NCI)
Poniard Pharmaceuticals
Hillel Yaffe Medical Center
Novacea
Aronex Pharmaceuticals